INNOVO

Our goal is to develop new drugs for patients suffering from intractable diseases such as idiopathic pulmonary fibrosis, osteoarthritis, ulcerative colitis, etc... Innovo has developed DeepZema®, an AI-augmented drug development platform, with all our efforts because we acknowledge how critical minimizing errors and increasing success rates in the new drug development process is. In addition, the expertise of the research faculty leads to the acceleration of R&D projects.

Registration numbers: 379-86-01520 (W)

Primary location: Daejeon Korea